GVHD, ACUTE
Clinical trials for GVHD, ACUTE explained in plain language.
Never miss a new study
Get alerted when new GVHD, ACUTE trials appear
Sign up with your email to follow new studies for GVHD, ACUTE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to prevent deadly transplant complication
Disease control Recruiting nowThis study tests whether combining three drugs—tacrolimus, methotrexate, and a new dosing schedule of anti-thymocyte globulin—can prevent acute graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia. About 29 adults aged 18-60 w…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New drug combo aims to tame deadly transplant complication
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for treating grade II acute graft-versus-host disease (GVHD), a common and serious complication after a stem cell transplant. The trial will enroll 168 people who have recen…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for stem cell transplant patients: drug combo targets deadly GVHD
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard steroids can better control severe graft-versus-host disease (GVHD) after a stem cell transplant. About 54 adults who develop severe GVHD within 100 days of their first transplant will receive the combination. The m…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 14, 2026 12:04 UTC